aluates Reports

$ 0.0

Automative

Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Research Report 2025

Published Date: September 2025

Report Code: QYRE-Auto-15H10278

Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Insights Forecast to 2028

BUY CHAPTERS

Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Research Report 2025

Code: QYRE-Auto-15H10278

Report

September 2025

Pages:85

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Bayer

Teva Pharmaceuticals

Empire Genomics

SeraCare Life Sciences

F.Hoffmann-La Roche

Neogenomics Laboratories

GlaxoSmithKline PLC

OncoDNA

Merck

Daiichi Sankyo

S Deciphera Pharmaceuticals

NTRK Fusion Gene Positive Advanced Solid Tumor Market

The global market for NTRK Fusion Gene Positive Advanced Solid Tumor was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

North American market for NTRK Fusion Gene Positive Advanced Solid Tumor is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for NTRK Fusion Gene Positive Advanced Solid Tumor is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global market for NTRK Fusion Gene Positive Advanced Solid Tumor in Hospitals and Clinics is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of NTRK Fusion Gene Positive Advanced Solid Tumor include Bayer, Teva Pharmaceuticals, Empire Genomics, SeraCare Life Sciences, F. Hoffmann-La Roche, NeoGenomics Laboratories, Glaxosmithkline, OncoDNA, Merck & Co., Daiichi Sankyo, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for NTRK Fusion Gene Positive Advanced Solid Tumor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding NTRK Fusion Gene Positive Advanced Solid Tumor.

The NTRK Fusion Gene Positive Advanced Solid Tumor market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global NTRK Fusion Gene Positive Advanced Solid Tumor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the NTRK Fusion Gene Positive Advanced Solid Tumor companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of NTRK Fusion Gene Positive Advanced Solid Tumor Market Report

Report Metric	Details
Report Name	NTRK Fusion Gene Positive Advanced Solid Tumor Market
Segment by Type	Therapeutics Diagnostics
Segment by Application	Hospitals and Clinics Cancer Centers Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Bayer, Teva Pharmaceuticals, Empire Genomics, SeraCare Life Sciences, F. Hoffmann-La Roche, NeoGenomics Laboratories, Glaxosmithkline, OncoDNA, Merck & Co., Daiichi Sankyo, S Deciphera Pharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of NTRK Fusion Gene Positive Advanced Solid Tumor company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the NTRK Fusion Gene Positive Advanced Solid Tumor Market report?

Ans: The main players in the NTRK Fusion Gene Positive Advanced Solid Tumor Market are Bayer, Teva Pharmaceuticals, Empire Genomics, SeraCare Life Sciences, F. Hoffmann-La Roche, NeoGenomics Laboratories, Glaxosmithkline, OncoDNA, Merck & Co., Daiichi Sankyo, S Deciphera Pharmaceuticals

What are the Application segmentation covered in the NTRK Fusion Gene Positive Advanced Solid Tumor Market report?

Ans: The Applications covered in the NTRK Fusion Gene Positive Advanced Solid Tumor Market report are Hospitals and Clinics, Cancer Centers, Others

What are the Type segmentation covered in the NTRK Fusion Gene Positive Advanced Solid Tumor Market report?

Ans: The Types covered in the NTRK Fusion Gene Positive Advanced Solid Tumor Market report are Therapeutics, Diagnostics

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Therapeutics

1.2.3 Diagnostics

1.3 Market by Application

1.3.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospitals and Clinics

1.3.3 Cancer Centers

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Perspective (2020-2031)

2.2 Global NTRK Fusion Gene Positive Advanced Solid Tumor Growth Trends by Region

2.2.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 NTRK Fusion Gene Positive Advanced Solid Tumor Historic Market Size by Region (2020-2025)

2.2.3 NTRK Fusion Gene Positive Advanced Solid Tumor Forecasted Market Size by Region (2026-2031)

2.3 NTRK Fusion Gene Positive Advanced Solid Tumor Market Dynamics

2.3.1 NTRK Fusion Gene Positive Advanced Solid Tumor Industry Trends

2.3.2 NTRK Fusion Gene Positive Advanced Solid Tumor Market Drivers

2.3.3 NTRK Fusion Gene Positive Advanced Solid Tumor Market Challenges

2.3.4 NTRK Fusion Gene Positive Advanced Solid Tumor Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top NTRK Fusion Gene Positive Advanced Solid Tumor Players by Revenue

3.1.1 Global Top NTRK Fusion Gene Positive Advanced Solid Tumor Players by Revenue (2020-2025)

3.1.2 Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue Market Share by Players (2020-2025)

3.2 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by NTRK Fusion Gene Positive Advanced Solid Tumor Revenue

3.4 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Concentration Ratio

3.4.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by NTRK Fusion Gene Positive Advanced Solid Tumor Revenue in 2024

3.5 Global Key Players of NTRK Fusion Gene Positive Advanced Solid Tumor Head office and Area Served

3.6 Global Key Players of NTRK Fusion Gene Positive Advanced Solid Tumor, Product and Application

3.7 Global Key Players of NTRK Fusion Gene Positive Advanced Solid Tumor, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 NTRK Fusion Gene Positive Advanced Solid Tumor Breakdown Data by Type

4.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Historic Market Size by Type (2020-2025)

4.2 Global NTRK Fusion Gene Positive Advanced Solid Tumor Forecasted Market Size by Type (2026-2031)

5 NTRK Fusion Gene Positive Advanced Solid Tumor Breakdown Data by Application

5.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Historic Market Size by Application (2020-2025)

5.2 Global NTRK Fusion Gene Positive Advanced Solid Tumor Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size (2020-2031)

6.2 North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2020-2025)

6.4 North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size (2020-2031)

7.2 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2020-2025)

7.4 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size (2020-2031)

8.2 Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region (2020-2025)

8.4 Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size (2020-2031)

9.2 Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2020-2025)

9.4 Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size (2020-2031)

10.2 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2020-2025)

10.4 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Bayer

11.1.1 Bayer Company Details

11.1.2 Bayer Business Overview

11.1.3 Bayer NTRK Fusion Gene Positive Advanced Solid Tumor Introduction

11.1.4 Bayer Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025)

11.1.5 Bayer Recent Development

11.2 Teva Pharmaceuticals

11.2.1 Teva Pharmaceuticals Company Details

11.2.2 Teva Pharmaceuticals Business Overview

11.2.3 Teva Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Introduction

11.2.4 Teva Pharmaceuticals Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025)

11.2.5 Teva Pharmaceuticals Recent Development

11.3 Empire Genomics

11.3.1 Empire Genomics Company Details

11.3.2 Empire Genomics Business Overview

11.3.3 Empire Genomics NTRK Fusion Gene Positive Advanced Solid Tumor Introduction

11.3.4 Empire Genomics Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025)

11.3.5 Empire Genomics Recent Development

11.4 SeraCare Life Sciences

11.4.1 SeraCare Life Sciences Company Details

11.4.2 SeraCare Life Sciences Business Overview

11.4.3 SeraCare Life Sciences NTRK Fusion Gene Positive Advanced Solid Tumor Introduction

11.4.4 SeraCare Life Sciences Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025)

11.4.5 SeraCare Life Sciences Recent Development

11.5 F. Hoffmann-La Roche

11.5.1 F. Hoffmann-La Roche Company Details

11.5.2 F. Hoffmann-La Roche Business Overview

11.5.3 F. Hoffmann-La Roche NTRK Fusion Gene Positive Advanced Solid Tumor Introduction

11.5.4 F. Hoffmann-La Roche Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025)

11.5.5 F. Hoffmann-La Roche Recent Development

11.6 NeoGenomics Laboratories

11.6.1 NeoGenomics Laboratories Company Details

11.6.2 NeoGenomics Laboratories Business Overview

11.6.3 NeoGenomics Laboratories NTRK Fusion Gene Positive Advanced Solid Tumor Introduction

11.6.4 NeoGenomics Laboratories Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025)

11.6.5 NeoGenomics Laboratories Recent Development

11.7 Glaxosmithkline

11.7.1 Glaxosmithkline Company Details

11.7.2 Glaxosmithkline Business Overview

11.7.3 Glaxosmithkline NTRK Fusion Gene Positive Advanced Solid Tumor Introduction

11.7.4 Glaxosmithkline Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025)

11.7.5 Glaxosmithkline Recent Development

11.8 OncoDNA

11.8.1 OncoDNA Company Details

11.8.2 OncoDNA Business Overview

11.8.3 OncoDNA NTRK Fusion Gene Positive Advanced Solid Tumor Introduction

11.8.4 OncoDNA Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025)

11.8.5 OncoDNA Recent Development

11.9 Merck & Co.

11.9.1 Merck & Co. Company Details

11.9.2 Merck & Co. Business Overview

11.9.3 Merck & Co. NTRK Fusion Gene Positive Advanced Solid Tumor Introduction

11.9.4 Merck & Co. Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025)

11.9.5 Merck & Co. Recent Development

11.10 Daiichi Sankyo

11.10.1 Daiichi Sankyo Company Details

11.10.2 Daiichi Sankyo Business Overview

11.10.3 Daiichi Sankyo NTRK Fusion Gene Positive Advanced Solid Tumor Introduction

11.10.4 Daiichi Sankyo Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025)

11.10.5 Daiichi Sankyo Recent Development

11.11 S Deciphera Pharmaceuticals

11.11.1 S Deciphera Pharmaceuticals Company Details

11.11.2 S Deciphera Pharmaceuticals Business Overview

11.11.3 S Deciphera Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Introduction

11.11.4 S Deciphera Pharmaceuticals Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025)

11.11.5 S Deciphera Pharmaceuticals Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Bayer

Teva Pharmaceuticals

Empire Genomics

SeraCare Life Sciences

F.Hoffmann-La Roche

Neogenomics Laboratories

GlaxoSmithKline PLC

OncoDNA

Merck

Daiichi Sankyo

S Deciphera Pharmaceuticals

List of Tables

Table 1. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Therapeutics

Table 3. Key Players of Diagnostics

Table 4. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Region (2020-2025)

Table 8. Global NTRK Fusion Gene Positive Advanced Solid Tumor Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Region (2026-2031)

Table 10. NTRK Fusion Gene Positive Advanced Solid Tumor Market Trends

Table 11. NTRK Fusion Gene Positive Advanced Solid Tumor Market Drivers

Table 12. NTRK Fusion Gene Positive Advanced Solid Tumor Market Challenges

Table 13. NTRK Fusion Gene Positive Advanced Solid Tumor Market Restraints

Table 14. Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Players (2020-2025)

Table 16. Global Top NTRK Fusion Gene Positive Advanced Solid Tumor Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor as of 2024)

Table 17. Ranking of Global Top NTRK Fusion Gene Positive Advanced Solid Tumor Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by NTRK Fusion Gene Positive Advanced Solid Tumor Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of NTRK Fusion Gene Positive Advanced Solid Tumor, Headquarters and Area Served

Table 20. Global Key Players of NTRK Fusion Gene Positive Advanced Solid Tumor, Product and Application

Table 21. Global Key Players of NTRK Fusion Gene Positive Advanced Solid Tumor, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue Market Share by Type (2020-2025)

Table 25. Global NTRK Fusion Gene Positive Advanced Solid Tumor Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue Market Share by Type (2026-2031)

Table 27. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue Market Share by Application (2020-2025)

Table 29. Global NTRK Fusion Gene Positive Advanced Solid Tumor Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue Market Share by Application (2026-2031)

Table 31. North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2026-2031) & (US$ Million)

Table 46. Bayer Company Details

Table 47. Bayer Business Overview

Table 48. Bayer NTRK Fusion Gene Positive Advanced Solid Tumor Product

Table 49. Bayer Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025) & (US$ Million)

Table 50. Bayer Recent Development

Table 51. Teva Pharmaceuticals Company Details

Table 52. Teva Pharmaceuticals Business Overview

Table 53. Teva Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Product

Table 54. Teva Pharmaceuticals Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025) & (US$ Million)

Table 55. Teva Pharmaceuticals Recent Development

Table 56. Empire Genomics Company Details

Table 57. Empire Genomics Business Overview

Table 58. Empire Genomics NTRK Fusion Gene Positive Advanced Solid Tumor Product

Table 59. Empire Genomics Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025) & (US$ Million)

Table 60. Empire Genomics Recent Development

Table 61. SeraCare Life Sciences Company Details

Table 62. SeraCare Life Sciences Business Overview

Table 63. SeraCare Life Sciences NTRK Fusion Gene Positive Advanced Solid Tumor Product

Table 64. SeraCare Life Sciences Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025) & (US$ Million)

Table 65. SeraCare Life Sciences Recent Development

Table 66. F. Hoffmann-La Roche Company Details

Table 67. F. Hoffmann-La Roche Business Overview

Table 68. F. Hoffmann-La Roche NTRK Fusion Gene Positive Advanced Solid Tumor Product

Table 69. F. Hoffmann-La Roche Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025) & (US$ Million)

Table 70. F. Hoffmann-La Roche Recent Development

Table 71. NeoGenomics Laboratories Company Details

Table 72. NeoGenomics Laboratories Business Overview

Table 73. NeoGenomics Laboratories NTRK Fusion Gene Positive Advanced Solid Tumor Product

Table 74. NeoGenomics Laboratories Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025) & (US$ Million)

Table 75. NeoGenomics Laboratories Recent Development

Table 76. Glaxosmithkline Company Details

Table 77. Glaxosmithkline Business Overview

Table 78. Glaxosmithkline NTRK Fusion Gene Positive Advanced Solid Tumor Product

Table 79. Glaxosmithkline Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025) & (US$ Million)

Table 80. Glaxosmithkline Recent Development

Table 81. OncoDNA Company Details

Table 82. OncoDNA Business Overview

Table 83. OncoDNA NTRK Fusion Gene Positive Advanced Solid Tumor Product

Table 84. OncoDNA Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025) & (US$ Million)

Table 85. OncoDNA Recent Development

Table 86. Merck & Co. Company Details

Table 87. Merck & Co. Business Overview

Table 88. Merck & Co. NTRK Fusion Gene Positive Advanced Solid Tumor Product

Table 89. Merck & Co. Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025) & (US$ Million)

Table 90. Merck & Co. Recent Development

Table 91. Daiichi Sankyo Company Details

Table 92. Daiichi Sankyo Business Overview

Table 93. Daiichi Sankyo NTRK Fusion Gene Positive Advanced Solid Tumor Product

Table 94. Daiichi Sankyo Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025) & (US$ Million)

Table 95. Daiichi Sankyo Recent Development

Table 96. S Deciphera Pharmaceuticals Company Details

Table 97. S Deciphera Pharmaceuticals Business Overview

Table 98. S Deciphera Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Product

Table 99. S Deciphera Pharmaceuticals Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025) & (US$ Million)

Table 100. S Deciphera Pharmaceuticals Recent Development

Table 101. Research Programs/Design for This Report

Table 102. Key Data Information from Secondary Sources

Table 103. Key Data Information from Primary Sources

Table 104. Authors List of This Report

List of Figures

Figure 1. NTRK Fusion Gene Positive Advanced Solid Tumor Picture

Figure 2. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Type: 2024 VS 2031

Figure 4. Therapeutics Features

Figure 5. Diagnostics Features

Figure 6. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2020-2031) & (US$ Million)

Figure 7. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Application: 2024 VS 2031

Figure 8. Hospitals and Clinics Case Studies

Figure 9. Cancer Centers Case Studies

Figure 10. Others Case Studies

Figure 11. NTRK Fusion Gene Positive Advanced Solid Tumor Report Years Considered

Figure 12. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 13. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Region: 2024 VS 2031

Figure 15. Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Players in 2024

Figure 16. Global Top NTRK Fusion Gene Positive Advanced Solid Tumor Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in NTRK Fusion Gene Positive Advanced Solid Tumor as of 2024)

Figure 17. The Top 10 and 5 Players Market Share by NTRK Fusion Gene Positive Advanced Solid Tumor Revenue in 2024

Figure 18. North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 19. North America NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Country (2020-2031)

Figure 20. United States NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. Canada NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Country (2020-2031)

Figure 24. Germany NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. France NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. U.K. NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Italy NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Russia NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Nordic Countries NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Region (2020-2031)

Figure 32. China NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Japan NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. South Korea NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Southeast Asia NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. India NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Australia NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Country (2020-2031)

Figure 40. Mexico NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Brazil NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Share by Country (2020-2031)

Figure 44. Turkey NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Saudi Arabia NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. UAE NTRK Fusion Gene Positive Advanced Solid Tumor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Bayer Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025)

Figure 48. Teva Pharmaceuticals Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025)

Figure 49. Empire Genomics Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025)

Figure 50. SeraCare Life Sciences Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025)

Figure 51. F. Hoffmann-La Roche Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025)

Figure 52. NeoGenomics Laboratories Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025)

Figure 53. Glaxosmithkline Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025)

Figure 54. OncoDNA Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025)

Figure 55. Merck & Co. Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025)

Figure 56. Daiichi Sankyo Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025)

Figure 57. S Deciphera Pharmaceuticals Revenue Growth Rate in NTRK Fusion Gene Positive Advanced Solid Tumor Business (2020-2025)

Figure 58. Bottom-up and Top-down Approaches for This Report

Figure 59. Data Triangulation

Figure 60. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Tumor Gene Test Service Market Research Report 2025

Global Solid Tumor Detection Market Research Report 2024

Fusion Biopsy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Gene Detection for Individualized Cancer Therapy Market Research Report 2024

Global Rare NGR1 Fusion Market Research Report 2024

Global ALK Positive Lung Cancer Treatment Market Insights Forecast to 2030

Global Rapid Tumor Marker Tests Market Research Report 2025

Solid Tumor Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Gene Therapy in Oncology Market Research Report 2024

Global Primary Tumor Cell Culture Market Research Report 2024

Global Tumor Embolization Market Research Report 2024

Global Tumor Markers Detection Kit Market Research Report 2025

Global Emerging Cancer Diagnostics Market Research Report 2024

Next Generation Cancer Diagnostics Market

Global Genomic Testing in Cancer Market Research Report 2024

Global Cancer Genomic Testing Market Research Report 2024

Global Prostate Cancer Molecular Diagnostics Market Research Report 2024

Cancer Gene Testing Service Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Gene Chip Market Research Report 2025

RELATED REPORTS

Global Fixation Device for Radiotherapy Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-4H16852

Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Group A Streptococcus for Injection Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-37K16619

Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Boron Neutron Capture Therapy System Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-30U16301

Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Radioactive Glass Microsphere Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-2G16953

Thu Sep 25 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions